Prognostic factors in patients with localized Ewing's sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapy

Journal of Chemotherapy

Volumn 9, Issue 5, 1997, Pages 352-363

  Delepine, N ^a   Delepine, G ^b   Cornille, H ^a   Voisin, M C ^b   Brun, B ^b   Desbois, J C ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Dactinomycin; Dose intensity; Ewing's sarcoma; Induction chemotherapy; Vincristine

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; IFOSFAMIDE; PIRARUBICIN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; EWING SARCOMA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PROGNOSIS; SKIN TOXICITY; TUMOR NECROSIS;

EID: 0030775266     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.5.352     Document Type: Article

References (30)

1. Sneath RS, Carter SR, Grimer RJ. Ewing's sarcoma. Fifteen years of experience. Chir Organi Mov 1990; 80 suppl 1: 260-61.
2. Barbieri E, Emiliano Zini G, Mancini A, et al. Combined therapy of localised Ewing's sarcoma of bone. Analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 1990; 19: 1165-70.
3. Jürgens H, Exner U, Gadner U, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6 year experience of an European cooperative trial. Cancer 1988; 61; 23-32.
4. Evans RG, Nesbit ME, Gehan EA, et al. Multimodal therapy for the management of localised Ewing's sarcoma of pelvic and sacral bones. A report from the second intergroup study. J Clin Oncol 1991; 7: 1173-80.
5. Nesbit ME, Perez, CA, Teeft M, et al. Multimodal therapy for the management ot primary non metastatic Ewing's sarcoma of bone: an intergroup study. Natl Cancer Inst Monogr 1981; 56: 255-62.
6. Klaassen R, Sastregarau X, Aurias A, et al. Sarcome d'Ewing osseux de l'adulte. Etude anatomoclinique de 30 observations. Bull Cancer 1992; 79: 161-7.
7. Bacci G, Picci P, Gitelis S, Borghi A, Campanacci M. The treatment of localised Ewing's sarcoma: the experience at the Istituto Ortopedico Rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer 1982; 49: 1561-70.
8. Glaubiger DL, Makuch R, Schwarz J, Levine AS, Johnson RE. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980; 45: 2213-9.
9. Marcus RB, Million RR. The effect of primary tumor size on the prognosis of Ewing's sarcoma. Int J Radiat Oncol Biol Phys 1984; 10 (suppl): 2-8.
10. Hayes FA, Thompson EI, Meyer WA, et al. Therapy for localised Ewing's sarcoma of bone. J Clin Oncol 1989; 7: 208-13.
11. Cangir C, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887-93.
12. Vietti TJ, Gehan EA, Nesbit ME Jr, et al. Multimodal therapy in metastatic Ewing's sarcoma: an intergroup study. Natl Cancer Inst Monogr 1981; 56: 279-84.
13. Sinkovics JG, Plager C, Ayola AG, Lindberg RD, Samuela ML. Ewing's sarcoma. Its course and treatment in 50 adults patients. Oncology 1980; 37: 114-9.
14. Bullimore JA. Ewing's sarcoma in adults. Clin Oncol 1990; 2, (1): 39-45.
15. Oberlin O, Habrand JL, Zücker JM, et al. No benefit of IFX in Ewing's sarcoma: a non randomised study of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1407-12.
16. Oberlin O, Zucker JM, Brunat-Mentigny M, et al. Prognostic factors in localised Ewing's sarcoma. A study of the French Society of Pediatric Oncology. Med Ped Oncol 1993; 21, 8: 573 (abstract 74, XXV SIOP meeting).
17. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in non metastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11: 1763-69.
18. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Ortho 1980; 153: 106-10.
19. Lewis RJ, Marcove RC, Rosen G. Ewing's sarcoma - functional effects of radiation therapy. J Bone Joint Surg 1977; 59A: 325-32.
20. Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T, Shatt IC. Radiation induced sarcoma of bone. Cancer 1971; 28: 1087-99.
21. Li FP. Second malignant tumors after cancer in childhood. Cancer 1977; 40: 1899-902.
22. Strong LC, Hersen J, Osborne BM, Salow WN. Risk of radiation related subsequent malignant tumor in survivors of Ewing's sarcoma. J Natl Cancer Inst, 1979; 62: 1401-06.
23. Markowska B, Delepine N, Delepine G, et al. Low cardiotoxicity of pirarubicin in solid tumors in children; an analysis of 71 cases. (abstract) J Clin Oncol 1994; 13: 413.
24. Siegel RD, Ryan LM, Amman KH. Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana Farber Cancer Institute. Am J Clin Oncol 1988; 11, 6: 614-7.
25. Meyer RM, Hryniuk WM, Goodyear MDE. The role of dose intensity in determining outcome of intermediate-grade-non-Hodgkin's lymphoma. J Clin Oncol 1991; 9: 339-47.
26. Nesbit ME, Gehan EA, Burgert EO, et al. Multimodal therapy for the management of primary non metastatic Ewing's sarcoma of bone. A long term follow up of the first intergroup study. J Clin Oncol 1990; 8, 10: 1664-74.
27. Evans R, Nesbit M, Askin F, et al. Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of the primary and surgical history in 62 patients presenting with non metastatic Ewing's sarcoma of the pelvic bones. Int J Rad Oncol Biol Physiol 1985; 11: 129-36.
28. Burgert EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of non pelvic localised Ewing's sarcoma of bone. Intergroup study IESS II. J Oncol 1990; 8: 1514-24.
29. Smith MA, Ungerleider RS, Horowitz ME. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83, 20: 1460-70.
30. Haim N, Epelbaum R, Ben-shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 73: 2515-9.